The U.S. Election Cannabis Playbook Part 2
A step by step guide to buying cannabis stocks under any election scenario. Individual portfolios for every election night outcome.
Read More»
The U.S. Election Cannabis Playbook Part 1
Breaking down the future of cannabis legalization depending on how Americans vote in the 2020 elections.
Read More»
Aphria 1Q 2021 Earnings – Prices in Freefall
Aphria is putting up the best results in Canada but when compared against US peers, investors need to be looking elsewhere. Opportunity cost matters.
Read More»WITH CHRISTOPHER WOOD
Internationally renowned for his salient predictions of market bubbles, Chris provides global investment insights in his weekly column 'Macro Battleship'.
The Affirm IPO is a Bet on the Future of Peloton
Affirm will run as long as Peloton doesn’t sink it first.
Read More»
Airbnb IPO: Don’t Sleep on This King of Home Rentals
The king of the home rental market is finally going public. How we get to a $500 stock price.
Read More»
C3.ai IPO – Houston We Have a Growth Problem
Is C3.ai the overlooked and undervalued IPO of December?
Read More»
Trulieve CEO Kim Rivers Doesn’t Need Debt to Grow
Kim Rivers talks catalysts, why she doesn’t like debt and where future growth is going to come from in this exclusive interview.
Read More»
Marijuana Investor Roundup: Analysis of the Week’s Most Important Events (Apr 25th, 2020)
A weekly review of only the most important cannabis news to impact your portfolio
Read More»
Organigram Announces $49M At-The-Market Equity Program
As we feared and warned investors about earlier, the company has announced today that it is doing a at-the-market equity raise program valued at $49M.
Read More»
The X for Boys – Teaching Trade Skills to Change Lives
Grizzle is capping off 2020 on a high note, an inspiring interview with King Randall from The X for Boys – changing lives by teaching trade skills.
Read More»
Markets & COVID-19: Dave Collum – Prof. of Organic Chemistry at Cornell
Grizzle interviews Dave Collum, Prof. of Organic Chemistry at Cornell; an engaging chat about markets, gold, covid-19 and all points between.
Read More»
Is Peloton Stock a Buy After Crushing Q4 Earnings?
Are investor’s getting a deal with Peloton or are good times already priced in?
Read More»PSYCHEDELICS
Why Compass Pathways (CMPS) is a 5-bagger: $210/share
Grizzle outlines the structural share price upside of Compass Pathways and its psilocybin drug: COMP 360 to treat depression.
Read More»
The Most Anticipated Psychedelic IPO: Compass Pathways (CMPS)
Grizzle sits down with Terry Chong (Partner, Grizzle Venture) to discuss one of the most anticipated psychedelic IPOs: Compass Pathaways
Read More»
AS FEATURED ON
